4.8 Article

Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 10, Issue 8, Pages 6904-6916

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.7b18525

Keywords

nitric oxide-delivering; high-density lipoprotein-like nanoparticles; biomimetic; nanotherapy; vascular disease; S-nitrosylation

Funding

  1. NTU-NU Institute for Nanomedicine
  2. NIH/NHLBI [BRP 5R01HL116577, T32HL094293]
  3. NIH [R01CA167041]
  4. CRN Regenerative Nanomedicine Catalyst Award Program at the Northwestern University
  5. Simpson Querrey Institute for BioNanotechnology
  6. Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource [NSF NNCI-1542205]
  7. MRSEC program at the Materials Research Center [NSF DMR-1121262]
  8. International Institute for Nanotechnology (TIN)
  9. Keck Foundation
  10. State of Illinois, through the IIN
  11. U.S. Army Research Office
  12. U.S. Army Medical Research and Material Command
  13. Northwestern University
  14. NCI CCSG [P30 CA060553]

Ask authors/readers for more resources

Disorders of blood vessels cause a range of severe health problems. As a powerful vasodilator and cellular second messenger, nitric oxide (NO) is known to have beneficial vascular functions. However, NO typically has a short half-life and is not specifically targeted. On the other hand, high-density lipoproteins (HDLs) are targeted natural nanoparticles (NPs) that transport cholesterol in the systemic circulation and whose protective effects in vascular homeo-stasis overlap with those of NO. Evolving the AuNP-templated HDL-like nanoparticles (HDL NPs), a platform of bioinspired HDL, we set up a targeted biomimetic nanotherapy for vascular disease that combines the functions of NO and HDL. A synthetic S-nitrosylated (SNO) phospholipid (1,2-dipalmitoyl-sn-glycero-3-phosphonitrosothioethanol) was synthesized and assembled with S-containing phospholipids and the principal protein of HDL, apolipoprotein A-I, to construct NO-delivering HDL-like particles (SNO HDL NPs). SNO HDL NPs self-assemble under mild conditions similar to natural processes, avoiding the complex postassembly modification needed for most synthetic NO-release nanoparticles. In vitro data demonstrate that the SNO HDL NPs merge the functional properties of NO and HDL into a targeted nanocarrier. Also, SNO HDL NPs were demonstrated to reduce ischemia/reperfusion injury in vivo in a mouse kidney transplant model and atherosclerotic plaque burden in a mouse model of atherosclerosis. Thus, the synthesis of SNO HDL NPs provides not only a bioinspired nanotherapy for vascular disease but also a foundation to construct diversified multifunctional platforms based on HDL NPs in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available